Clinical trials in systemic sclerosis: Lessons learned and outcomes

30Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The pathogenesis of systemic sclerosis (SSc) is complex and largely unclear. The clinical heterogeneity of the disease and its progression over a number of years makes the choice of endpoints in the design of clinical trials difficult. The overwhelming need in this disease is to diagnose it early and identify those patients who will benefit most from early, aggressive treatment that potentially can alter the clinical disease course. To achieve this, innumerable challenges must be overcome. This article reviews data from recent clinical trials and the lessons derived from retrospective observational studies, databases, and patient registries. Taken together, these observations will help to improve our understanding of the diverse clinical course of SSc and permit refinement of existing outcome measures for the design of future clinical trials, in which the likelihood of observing a positive treatment effect with the drugs at our disposal will be maximized. © 2007 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Matucci-Cerinic, M., Steen, V. D., Furst, D. E., & Seibold, J. R. (2007, August 15). Clinical trials in systemic sclerosis: Lessons learned and outcomes. Arthritis Research and Therapy. https://doi.org/10.1186/ar2191

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free